Vol. 5 No. 1 (2025)
Reimbursement Reviews

Remdesivir (Veklury)

decorative image of the issue cover

Published January 8, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses remdesivir (Veklury), 100 mg/vial, IV infusion.
  • Indication: For the treatment of COVID-19 in hospitalized adults and pediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen.